文献速递生殖医学

皮下与阴道联合肌注黄体酮在程序化冻融囊胚移植中的比较

Subcutaneous Progesterone versus Vaginal Progesterone Supplemented with Intramuscular Progesterone Every Third Day in Programmed Vitrified-Warmed Blastocyst Transfer Cycles.
PubMed 文献 · Fertil Steril · 2026-10-26

两组持续妊娠率分别为53.6%和54.4%,调整后无统计学显著差异(aRR 0.95,95%CI 0.81-1.13)。血清黄体酮中位数分别为23.48和22.90 ng/mL(p=0.543),未发现血清黄体酮与持续妊娠的明确关联。

要点

  • 皮下黄体酮与阴道联合肌注黄体酮方案的持续妊娠率无显著差异。
  • 两组血清黄体酮分布重叠,中位数分别为23.48和22.90 ng/mL。
  • 研究设计不能推断因果或等效性/非劣效性。

核心结论

  • 皮下黄体酮25mg每12小时与阴道黄体酮90mg每12小时联合肌注黄体酮50mg每3天相比,持续妊娠率无统计学显著差异。

研究设计与样本

  • 皮下黄体酮组451例,阴道联合肌注组169例,方案按序贯非重叠日历周期使用。

主要发现

  • 持续妊娠率皮下组53.6%,阴道联合肌注组54.4%(粗率差-0.9个百分点,95%CI -9.5至7.9)。
  • 调整协变量后标准化风险分别为53.6%和56.2%(调整率差-2.6个百分点,95%CI -12.0至6.7;aRR 0.95,95%CI 0.81-1.13)。
  • 血清黄体酮中位数皮下组23.48 ng/mL(四分位距18.72-29.46),阴道联合肌注组22.90 ng/mL(四分位距18.50-29.40),p=0.543。
  • 百分位分析和连续建模均未发现观察范围内血清黄体酮浓度与持续妊娠的明确关联。

临床怎么用

  • 在程序化冻融囊胚移植周期中,皮下黄体酮方案可作为阴道联合肌注黄体酮方案的替代选择之一。
  • 血清黄体酮监测在观察范围内对持续妊娠的预测价值有限,不宜单独据此调整黄体支持。

局限性

  • 回顾性设计无法推断因果。
  • 统计不精确,不能得出等效性或非劣效性结论。
  • 两组方案按非重叠日历周期使用,可能存在时间偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare ongoing pregnancy rates between subcutaneous progesterone and vaginal progesterone supplemented with intramuscular progesterone every third day in programmed frozen embryo transfer cycles. DESIGN: Retrospective cohort study. SUBJECTS: Six hundred twenty patients undergoing their first vitrified-warmed blastocyst transfer with a programmed protocol at a single tertiary center between March 2018 and June 2023; no exclusion criteria were applied. EXPOSURE: Following 10 to 12 days of estradiol valerate 6 mg/day, 451 patients received subcutaneous progesterone 25 mg every 12 hours, and 169 patients received vaginal progesterone gel 90 mg every 12 hours supplemented with intramuscular progesterone 50 mg every third day (days 1, 4, and 7 of progesterone start). The regimens were used during sequential, nonoverlapping calendar periods. MAIN OUTCOME MEASURES: Ongoing pregnancy rate. Serum progesterone was measured on the fifth day of progesterone administration (one day before transfer), 4 to 5 hours after the morning dose. Associations between serum progesterone and ongoing pregnancy were evaluated using regimen-specific percentile categories and continuous modeling. Adjusted risk ratios (aRRs) were estimated using modified Poisson regression. RESULTS: Ongoing pregnancy rates were 53.6% versus 54.4% in the subcutaneous and vaginal plus intramuscular groups, respectively (crude risk difference: -0.9 percentage points; 95% CI: -9.5 to 7.9). After covariate adjustment, standardized risks were 53.6% and 56.2%, respectively (adjusted risk difference: -2.6 percentage points; 95% CI: -12.0 to 6.7; aRR: 0.95; 95% CI: 0.81-1.13). Median serum progesterone was 23.48 ng/mL (interquartile range 18.72-29.46) versus 22.90 ng/mL (interquartile range 18.50-29.40), respectively (p=0.543). Neither the percentile-based analyses nor continuous modeling identified a clear association between serum progesterone concentration and ongoing pregnancy within the observed ranges. CONCLUSION: No statistically significant difference in ongoing pregnancy was observed between subcutaneous progesterone 25 mg every 12 hours and vaginal progesterone 90 mg every 12 hours supplemented with intramuscular progesterone 50 mg every third day. Serum P4 distributions overlapped between groups. However, the study design and statistical imprecision preclude causal inference and conclusions of equivalence or non-inferiority.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Mumusoglu S, Ince O, Erden M, et al. Subcutaneous Progesterone versus Vaginal Progesterone Supplemented with Intramuscular Progesterone Every Third Day in Programmed Vitrified-Warmed Blastocyst Transfer Cycles. Fertil Steril. 2026. PMID: 42933587. doi:10.1016/j.fertnstert.2026.10.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。